CONCEPT FRAMEWORK — CONFIDENTIAL
GETWELL CANCER HOSPITAL · DIGITAL TRANSFORMATION

Onco-CoE
Cancer Care
Patient OncoCare Intelligence Platform

A precision patient navigation operating system that orchestrates every touchpoint of a cancer patient's journey — from first diagnosis to last follow-up — across a hub-and-spoke care network reaching every pin code.

500Bed Hub Hospital
Spoke Partners
20+AI Flagship Modules
0Missed Waypoints
SCROLL TO EXPLORE
01 / THE VISION

The Patient OncoCare
Intelligence Platform

Just as an air traffic controller ensures every aircraft moves safely, on schedule, and without conflict — Onco-CoE ensures every cancer patient moves through their care pathway with zero dropped handoffs, zero scheduling conflicts, and proactive course corrections.

Every Patient is a Flight Plan. Every Clinician is a Controller. Every Touchpoint is a Waypoint.

Flight Plan = Care Pathway

From diagnosis to survivorship, every patient receives a dynamic, AI-generated care plan — a "flight plan" — that defines all waypoints: consultations, labs, imaging, chemotherapy cycles, surgical windows, radiation fractions, and home care touchpoints. The plan self-updates as clinical data changes.

📡

Radar = Real-Time Patient Visibility

A unified command center gives clinical coordinators live visibility of every active patient: their current phase, next scheduled event, pending labs, and any risk flags. Like ATC radar, no patient ever disappears from the screen. Alerts fire before problems occur, not after.

🔀

Runway Coordination = Resource Orchestration

Chemotherapy chairs, OT slots, radiation linac time, and oncologist availability are orchestrated as shared national resources. Conflicts are flagged in advance. Priority sequencing ensures the most critical patients get bandwidth first, while routine care flows without bottlenecks.

≤24h Time from diagnosis to
first care plan generation
100% Chemo cycle adherence
tracked automatically
0-lag Surgical-to-radiation
handoff coordination
Home Last-mile care delivered at
patient's pin code
AI Toxicity alerts before
next appointment
FHIR Universal interoperability
across all spokes
02 / COMMAND CENTER

The Onco-CoE
Command Center

A real-time hospital operations dashboard — the "tower" from which patient navigators and coordinators manage the entire active patient population simultaneously.

LIVE PATIENTS
SCHEDULE
ALERTS
NETWORK
247ACTIVE PATIENTS
12ALERTS TODAY
98.4%ON-PATHWAY
ACTIVE PATIENT CARE BOARD — LIVE
RK
Ramesh Kumar, 54 · Breast Ca. Stage III
Cycle 4/6 · Paclitaxel + Carboplatin · Day 3 of 5 · Infusion Ward B-12
CHEMO
PD
Priya Desai, 41 · Ovarian Ca. Stage II
Debulking Surgery · OT-3 · Surgeon: Dr. Mehta · ETA 2h 20m
SURGERY
VS
Vinod Shah, 67 · Head & Neck Ca. Stage IV
IMRT Fraction 18/30 · Linac-2 · Next: Fraction 19 tomorrow 9:00 AM
RADIATION
AJ
Anita Joshi, 58 · Colorectal Ca. Post-Op Week 3
Home Care · Spoke: NursingPlus Surat · PIN 395001 · Next Hub Visit: 14 Mar
HOME CARE
MB
Meena Bhat, 48 · Lung Ca. · Staging Work-Up
Awaiting PET-CT Report · Tumor Board: 10 Mar · Pathway pending
STAGING
SP
Suresh Patel, 62 · Head & Neck Ca. Stage III
Pre-op Assessment · OT Scheduled: 12 Mar · Jetpur Spoke referral
PRE-OP
LIVE ALERTS
Toxicity Flag — R. KumarGrade 2 neutropenia. Dose modification required before Cycle 5.
Scheduling Gap — V. ShahNo transport for fraction 19. Spoke coordinator notified.
Home Care UpdateA. Joshi wound care complete. No complications.
Pathway GeneratedS. Patel · H&N Ca. pathway ready for Tumor Board.
03 / PATIENT JOURNEY

The Orchestrated
Patient Flight Plan

Every patient's care is mapped as a living, adaptive journey — automatically generated by AI, continuously monitored, and seamlessly shifted between hub and spoke as the clinical situation evolves.

WAYPOINT 01 · DETECTION

First Contact & AI-Powered Intake

Patient arrives via referral, walk-in, or spoke partner. AI pre-consultation health intake captures structured history. Digital registration creates a unified longitudinal record.

📋
AI Health IntakeStructured medical history collected before first consult
📍
Pin Code MappingPatient's home location mapped to nearest spoke partners
🔗
ABDM Health IDABHA linked. All records federated from day one
WAYPOINT 02 · DIAGNOSIS

Integrated Staging & Tumor Board

Pathology, genomics, imaging, and clinical data converge on a single digital tumor board. AI generates staging summary. All specialists see the same truth simultaneously.

🧬
AI RadiomicsTumor detection, sizing, and molecular risk markers
👥
Digital Tumor BoardMDT collaboration with full imaging and genomics
🗺
Pathway EngineAI auto-generates care pathway in under 24 hours
WAYPOINT 03 · TREATMENT

Orchestrated Multi-Modal Treatment

Surgery, chemotherapy, and radiation are scheduled as an integrated symphony — not as siloed department bookings. Conflicts are resolved before they happen. Handoffs are automatic.

💊
Smart Chemo SchedulerAuto-calculates dosing, infusion slots, and toxicity windows
Radiation SequencingAll 25–30 fractions scheduled at pathway generation
🔪
AI Surgical Planning3D reconstruction, risk scoring, OT coordination
WAYPOINT 04 · MONITORING

Remote Toxicity & Symptom Surveillance

Between visits, patients report symptoms via mobile app. AI monitors for early toxicity signals and flags complications before they escalate to emergencies, enabling spoke-level interventions.

📱
Patient App PRODaily symptom check-ins with AI triage engine
🚨
Escalation ProtocolAuto-alerts to nearest spoke nurse if flags triggered
WAYPOINT 05 · RECOVERY & SURVIVORSHIP

Home-First Care & Long-Term Follow-Up

Post-treatment care is delegated to spoke partners near the patient's home. Hub retains clinical governance. All data flows back to the hub via FHIR APIs. Long-term survivorship tracking automated.

🏠
Spoke Home CareNursing, infusion, and wound care at patient pin code
📊
Survivorship RegistryAI-tracked long-term outcomes and recurrence detection
🔁
TeleoncologyAll follow-ups virtual unless clinical intervention needed
04 / NETWORK ARCHITECTURE

Hub & Spoke
Care Network

Getwell Cancer Hospital operates as the central hub — the "tower" — while a federated network of partner clinics, nursing centers, diagnostic labs, and pharmacies extend its reach to every pin code in the patient's region.

● HUB · LEVEL 1

Getwell Cancer Hospital

The clinical command center. Houses full oncology capability: surgical suites, linac radiation, chemotherapy day care, tumor board, pathology, genomics, and imaging. All clinical decisions originate and are governed here.

Complex Surgery Radiation Therapy Chemo Day Care Tumor Board Genomics ICU Oncology Clinical Trials
◎ SPOKE · LEVEL 2

District Cancer Clinics

Oncologist-led outpatient centers handling routine chemo infusions, follow-up consultations, and oral chemotherapy management. Directly connected to hub EMR.

Infusion Suites OPD Oncology Teleconsult Relay
◎ SPOKE · LEVEL 3

Nursing & Home Care Centers

Nurse-led partner organizations providing post-surgical wound care, palliative support, vital monitoring, and medication administration at or near the patient's home.

Wound Care IV Administration Vitals Telemetry Palliative
◎ SPOKE · LEVEL 3

Diagnostic & Imaging Partners

NABL-accredited diagnostic labs and imaging centers distributed across cities. Reports auto-ingest into hub PACS and patient timeline within minutes of collection.

Blood Labs PET-CT Digital Pathology PACS Relay
◎ SPOKE · LEVEL 4

Community Pharmacy Network

Partnered pharmacies that dispense oral oncolytics and supportive medications to patients at their home pin code. Drug adherence tracked via scan-and-confirm app.

Oral Chemo Dispensing Adherence Tracking Cold Chain Logistics
◎ SPOKE · LEVEL 4

General Practitioner Network

Primary care physicians at every pin code serving as first-responders for symptom escalations and as trusted community links for patient education and early detection referrals.

Symptom Triage Referral Gateway Early Detection

Every Zip. Every Patient. Every Day.

The Onco-CoE platform maps each patient to available spoke partners within their pin code at onboarding. The system auto-assigns care teams, optimises travel distance, and maintains real-time partner capacity visibility.

🏥
HUB
Cancer Hospital
360 001
💉
CLINIC
Oncology OPD
360 002
🧪
LABS
Diagnostic Centre
360 004
🩺
HOME
Nursing Partner
395 001
💊
PHARMA
Community Rx
395 003
👨‍⚕️
GP
Primary Care
382 015
🖥
TELE
Teleconsult Node
380 006
📦
LOGISTICS
Sample Pickup
380 015
🫀
PALLIATIVE
Hospice Care
396 001
EXPAND
Onboard Partner
Any PIN
05 / AI FLAGSHIP MODULES

20 Signature
Innovations

The Onco-CoE platform is built on 20 AI-powered flagship capabilities that work in concert to deliver the air traffic control model across all clinical, operational, and patient-facing domains.

🗺
01

Smart Patient Navigation

Google Maps-like indoor navigation for OPD, chemo ward, radiology, and labs.

02

Live Wait-Time Tracking

Uber-style real-time queue visibility for patients and families.

🧠
03

AI Pre-Consult Intake

Structured medical history captured before first physician encounter.

📊
04

Patient Journey Dashboard

Patient views full treatment roadmap — diagnosis through survivorship.

🎙
05

AI Medical Scribe

Voice → structured clinical notes. Eliminates manual documentation burden.

⚕️
06

Clinical Decision Support

Real-time guideline suggestions at point of care based on diagnosis.

🧬
07

Oncology Protocol Builder

Auto-suggests NCCN-aligned chemo regimens for confirmed cancer type.

🔗
08

Unified Patient Timeline

Scans, pathology, chemo cycles, and surgery notes in one longitudinal view.

👥
09

Digital Tumor Board

All specialists review imaging, genomics, and plans in one collaborative platform.

🛣
10

AI Pathway Engine

End-to-end care pathway auto-generated within 24 hours of cancer confirmation.

🔬
11

AI Tumor Detection

Radiomics analysis: tumor size, progression, molecular risk markers from imaging.

🏗
12

3D Surgical Planning

CT/MRI-derived 3D reconstruction for preoperative surgical planning.

⚠️
13

AI Surgical Risk Prediction

Predicts complication risk, blood loss, and ICU requirements pre-operatively.

📝
14

Operative Note Automation

OT recording transcribed into structured operative notes automatically.

💊
15

Smart Chemo Management

Automated dosage calculation, infusion scheduling, and toxicity alert system.

📡
16

Remote Toxicity Monitoring

Patient symptom app feeds AI model that flags Grade 2+ events proactively.

🤖
17

Smart Nurse Task AI

AI prioritises medication times, urgent patients, and pending tasks per shift.

📦
18

Predictive Drug Procurement

Forecasts chemo drug demand, expiry risk, and supply chain replenishment.

🏛
19

Hospital Command Centre

Real-time bed occupancy, OT utilisation, chemo chair status, and patient flow.

📈
20

AI Oncology Research Platform

Automatically structures datasets for outcomes research and clinical trial matching.

06 / DATA ARCHITECTURE

The Intelligence
Fabric

Every module in Onco-CoE is connected through a standards-based interoperability layer — ensuring data flows freely, securely, and in real-time across the hub, all spokes, and the patient's mobile device.

Interoperability Standards

All data exchange built on open healthcare standards, ensuring vendor neutrality and future-proofing. Compatible with ABDM, NHA, and international health networks.

HL7 FHIR R4
Core
ABDM / ABHA
India
DICOM / PACS
Imaging
SNOMED CT
Coding
CDS Hooks / CQL
Rules
ICD-10 / TNM
Staging

AI & Analytics Architecture

The platform's intelligence layer processes clinical, operational, and patient-reported data in real-time — powering predictions, alerts, and automated pathway adjustments.

Pathway AI Engine
Core
Radiomics AI
Vision
Toxicity Predictor
NLP+ML
Surgical Risk Model
Predict
Clinical NLP Scribe
LLM
Demand Forecasting
Ops
08 / NATIONAL POLICY ALIGNMENT

Anchored in India's
National Cancer Mission

The Onco-CoE platform is purpose-built to operationalise the Government of India's healthcare vision articulated at the highest level — translating national policy commitments into hospital-level digital workflows and a regional care network.

"30 new cancer hospitals in 9 years. 10 more under construction. 1.5 lakh Ayushman Arogya Mandirs for early detection. This is India's model of healthcare reforms."

The Prime Minister's address at the foundation stone laying ceremony for the Getwell Trust Cancer Hospital & Research Centre articulated a three-pronged vision: accessibility through distributed infrastructure, affordability through price controls and Jan Aushadhi, and early detection through village-level screening mandirs. Onco-CoE is the digital operating system that makes all three actionable at scale.

30+10 Cancer hospitals built
+ 10 under construction
1.5L Ayushman Arogya Mandirs
for village-level screening
6Cr Beneficiaries of free
Ayushman Bharat treatment
₹1L Cr Out-of-pocket savings
for Indian patients
10,000 Jan Aushadhi Kendras
→ Target: 25,000
80% Discount on medicines
at Jan Aushadhi centres
₹30K Cr Annual hospital bill savings
via Jan Aushadhi
Apex Cancer Center — New national
CoE anchor for Saurashtra
📊 THEN vs NOW · GUJARAT MEDICAL INFRASTRUCTURE
METRIC
CIRCA 2002
2024
Medical Colleges
11
40
MBBS Seats
Baseline
5× Growth
PG Medical Seats
Baseline
3× Growth
Pharmacy Colleges
13
~100
Diploma Pharmacy
6
~30
Specialised CoE
None
Apex Cancer Center
🎯 Onco-CoE PLATFORM ALIGNMENT TO NATIONAL GOALS
🏥
Accessibility
Hub-spoke network extends GCH reach to every pin code in Saurashtra. Apex Cancer Center as Tier-0 CoE enables complex case referrals.
💊
Affordability — Jan Aushadhi Integration
Platform auto-flags Jan Aushadhi alternatives at prescription time. Drug adherence tracked across 25,000 partner kendras.
🔍
Early Detection — Aarogya Mandir Link
1.5 lakh Ayushman Arogya Mandirs feed cervical & breast cancer screening data directly into Onco-CoE via ABDM APIs.
🛡
Ayushman Bharat Claim Processing
NHCX-integrated claims engine ensures all 6 Cr+ beneficiaries receive cashless care without documentation friction.
GOVERNMENT SCHEME INTEGRATION · BUILT INTO Onco-CoE PLATFORM
🛡

Ayushman Bharat Yojana

Real-time NHCX claim initiation at point of registration. Auto-eligibility check via ABHA ID. Cashless discharge workflow for all covered procedures.

6 Cr+ beneficiaries
💊

Jan Aushadhi Kendra Network

Prescriptions auto-cross-referenced against Jan Aushadhi formulary. Nearest kendra mapped to patient pin code. Oral chemotherapy dispensing tracked for adherence.

80% cost savings
🌿

Ayushman Arogya Mandirs

Village-level screening results for cervical and breast cancer flow into Onco-CoE as structured FHIR records. Positive screens auto-trigger referral pathways to nearest spoke or hub.

1.5 lakh mandirs
🆔

ABHA / ABDM Ecosystem

Every patient's ABHA ID is the universal key linking their cancer journey across all tiers — from Aarogya Mandir screening to Apex Cancer Center tertiary care — without re-registration.

Universal health ID
🏛

Apex Cancer Center — Tier-0 CoE

Complex oncology cases requiring advanced genomics, proton therapy, or rare tumour boards are seamlessly referred via the Onco-CoE referral engine to Apex Cancer Center with full patient record transfer.

Regional apex anchor
🔬

National Cancer Registry

Anonymised, structured oncology data automatically flows to ICMR's National Cancer Registry. Onco-CoE becomes a data contributor to national cancer epidemiology and research.

Population-level data
09 / THREE-TIER CARE ARCHITECTURE

Apex Cancer Center → Onco-CoE → Community
A Three-Tier Oncology Ecosystem

The addition of Apex Cancer Center as the national Centre of Excellence creates a three-tier architecture: Tier-0 (Apex Cancer Center — apex national CoE), Tier-1 (Getwell Hospital — regional hub), and Tier-2/3 (district clinics, nursing centres, Aarogya Mandirs, GPs — community spokes). Each tier is digitally connected through Onco-CoE.

● TIER 0 · NATIONAL CENTRE OF EXCELLENCE

Apex Cancer Center

📍 Rajkot, Gujarat · ~63 km from Kagvad

The apex referral node for the entire Saurashtra region. Handles rare tumour boards, proton therapy, complex genomics, high-risk surgeries, and cutting-edge clinical trials. All Onco-CoE referrals arrive pre-loaded with complete FHIR patient record via secure ABDM data bridge.

Proton TherapyRare Tumour BoardsAdvanced Genomics Robotic SurgeryPhase I–III TrialsPET-CT / MR-Linac Complex ReconstructionApex Cancer Center Research Platform
🔗 Onco-CoE Integration: Seamless bi-directional patient record transfer via FHIR R4 + ABDM APIs. Onco-CoE tracks patient status during Apex Cancer Center care and re-integrates at discharge.
↕ REFERRAL & RETURN PATHWAY · FHIR + ABDM DATA BRIDGE
◈ TIER 1 · REGIONAL HUB HOSPITAL

Getwell Cancer Hospital & Research Centre

📍 Kagvad, Jetpur Taluka, Rajkot District · PIN 360370

The primary oncology hub for the Saurashtra region. Handles full-spectrum cancer care including surgery, chemo, radiation, tumor board, and palliative. The operational home of the Onco-CoE platform. Feeds upward to Apex Cancer Center and downward to all spokes.

OT × 4 SuitesIMRT / IGRT LinacChemo Day Care Digital Tumor BoardPathology & GenomicsInterventional Radiology 500-Bed InpatientOnco-CoE Command Centre
◈ TIER 1B · FUTURE EXPANSION (AMRELI)

Getwell Trust Cancer Hospital — Amreli

📍 Amreli District, Gujarat · New Foundation Stone Laid

The second regional hub, announced at the PM's address. Will mirror Kagvad's full oncology capability and serve the Amreli, Bhavnagar, and Gir Somnath districts. Onco-CoE will deploy as a parallel hub instance sharing the same spoke network and data fabric.

Full Oncology (Planned)Onco-CoE Hub Instance 2 Research & Clinical TrialsShared Data Fabric Amreli District Coverage
🚧 Foundation stone laid. Projected operational: 2027. Onco-CoE platform scalable to multi-hub topology from day one.
↕ CARE COORDINATION · FHIR APIs · SPOKE ASSIGNMENT ENGINE
◎ TIER 2A · DISTRICT ONCOLOGY CLINICS

District Cancer OPD Centres

📍 Jetpur · Gondal · Junagadh · Amreli

Oncologist-led centres for chemo infusions, follow-ups, and oral chemotherapy. Directly on the Onco-CoE network.

Infusion SuiteOPD OncoTeleconsult
◎ TIER 2B · DIAGNOSTIC & IMAGING

NABL Diagnostic & Imaging Centres

📍 District HQs & Taluka Towns

Labs and imaging nodes feeding results directly into Onco-CoE patient timelines. Auto-matched to pathways.

Blood LabsCT / MRIDigital Pathology
◎ TIER 2C · JAN AUSHADHI NETWORK

Jan Aushadhi Kendras

📍 10,000 → 25,000 Across India

Oncology prescriptions auto-routed for Jan Aushadhi fulfilment. 80% cost saving tracked per patient. Adherence data back to hub.

80% DiscountOral ChemoAdherence Tracking
◎ TIER 2D · NURSING & HOME CARE

Home Care & Nursing Partners

📍 Every Pin Code in Catchment

Nurse-led post-surgical and palliative care delivered at home. Vital telemetry and wound data sync to Onco-CoE in real-time.

Wound CareVitals TelemetryPalliative
↕ EARLY DETECTION & REFERRAL · ABDM HEALTH RECORDS
◎ TIER 3A · AYUSHMAN AROGYA MANDIRS

Village Screening Centres

📍 1.5 Lakh Centres Nationally

Cervical & breast cancer screening. Positive screens trigger auto-referral into Onco-CoE spoke pathway.

Cervical ScreenBreast ScreenAuto-Referral
◎ TIER 3B · PRIMARY CARE / GP NETWORK

Community GP Network

📍 All Pin Codes in Saurashtra

First-responders for symptom escalations from home care patients. Integrated with Onco-CoE alerts engine.

Symptom TriageAlert ResponseReferral Gateway
◎ TIER 3C · PATIENT & FAMILY

Patient App & Family Portal

📱 Mobile · Any Device · Any Language

Daily symptom check-ins, appointment visibility, drug reminders, and care plan access in Gujarati & Hindi.

Symptom Check-insCare Plan ViewGujarati UI
◎ TIER 3D · AYUSHMAN BHARAT CLAIMS

Financial Assistance Engine

💰 Cashless · NHCX-Integrated

Beneficiary verification, claim initiation, and approval workflow embedded into Onco-CoE registration. Zero friction for 6 Cr+ beneficiaries.

NHCX ClaimsABHA VerifyCashless Discharge
🏆

NCCN & WHO Guidelines Engine

All treatment pathway recommendations are validated against NCCN 2024 guidelines and WHO ESSO protocols. Clinical decision support fires at every prescribing event.

🤝

Multidisciplinary Team (MDT) Workflow

Every cancer diagnosis triggers a structured MDT workflow — mirroring best practice from UK's Cancer Alliance and US NCI cancer centres. Minimum 5 specialists per board.

📡

Remote Patient Monitoring (RPM)

Continuous wearable integration and symptom app reporting — aligned with ASCO's telehealth guidelines and proven to reduce unplanned ER visits by 38% in published trials.

🧬

Precision Oncology & Genomics

NGS-based biomarker testing integrated into the staging pathway. Results auto-populate the AI protocol builder with targeted therapy and immunotherapy recommendations.

🌍

Patient-Reported Outcomes (PROs)

EORTC QLQ-C30 quality-of-life assessments embedded in the patient app. PRO data feeds directly into the tumor board view and influences supportive care decisions.

🔐

Data Sovereignty & DISHA Compliance

All patient data governed under India's Digital Information Security in Healthcare Act (DISHA). On-premise deployment option for sensitive genomics data with zero export to foreign clouds.

10 / IMPLEMENTATION ROADMAP

From Vision to
Operations in 18 Months

A phased rollout that delivers quick wins in the first 90 days, then progressively activates the full ATC model and hub-spoke network over three structured phases.

PHASE 01

Foundation & Core ATC

Months 1–6
  • EMR deployment with AI medical scribe
  • Patient portal and mobile app launch
  • Command centre dashboard (hub-level)
  • Smart chemo management system
  • AI pathway engine (top 5 cancer types)
  • Digital tumor board platform
  • ABDM/ABHA integration
  • First 3 spoke partners onboarded
PHASE 02

Intelligence Activation

Months 7–12
  • Radiomics AI and PACS integration
  • Remote toxicity monitoring with app
  • Surgical planning AI module
  • Spoke network expansion (20+ partners)
  • Pin code-based care assignment engine
  • Pharmacy network integration
  • Predictive drug procurement AI
  • Clinical decision support (NCCN rules)
PHASE 03

Full ATC & Research Platform

Months 13–18
  • Full Saurashtra spoke network live (50+ partners)
  • Apex Cancer Center Tier-0 referral pathway live
  • Amreli Hub (GCH-2) Onco-CoE deployment
  • Ayushman Bharat + NHCX claims automation
  • Aarogya Mandir ABDM screening data ingestion
  • Jan Aushadhi formulary integration at all spokes
  • AI oncology research + ICMR registry contribution
  • Survivorship, palliative & long-term follow-up
11 / CITIZEN LONGEVITY INDEX & EARLY DETECTION

Citizen Longevity Index
& Early Detection Architecture

A population-health layer combining community-led early detection with globally validated Healthy Longevity Medicine diagnostics. The architecture begins at the community frontline — before any clinical encounter — and progresses through four rings to the hub. Every citizen receives a Longevity Quotient (LQ) derived from biomarkers across those rings.

70%

70% of cancer cases in the catchment present at Stage III or IV — due to social hesitation, delayed referrals, and absence of a trusted first point of contact.

Clinical diagnostic excellence at the hub cannot solve a problem that begins in the community. The Pilgrimage to Public Health Framework — grounded in Jan-Bhagidari (people's participation) — shifts cancer care from a reactive treatment model to a proactive community movement, converting cultural gathering points into the first layer of the detection network.

70%
LATE STAGE AT
PRESENTATION
5 min
GCH SCREENING
CHECKLIST
Weekly
VIRTUAL TUMOR
BOARDS
4 Rings
COMMUNITY TO
HUB PATHWAY
THE FOUR-RING CARE CONTINUUM · COMMUNITY TO HUB
Community Frontline
Jan-Bhagidari · Moksha Kshetras
ASHAs · ANMs · Panchayats · Community Volunteers · Cultural Gathering Points
FIRST CONVERSATION
FIRST DECISION
Universal Screening
Ayushman Arogya Mandirs
5-min GCH Checklist · Basic Biomarkers · Digital Referral Trigger · ABHA Enrolment
RAPID SCREENING
LQ RING 1
District Spoke
Spoke Diagnostic Centres (Onco-CoE Network)
Tele-oncology Navigation · Virtual Tumor Board · Day-care Infusion · NABL Diagnostics
DIAGNOSIS & NAV
LQ RING 2
Hub / CoE
Getwell Cancer Hospital (Moksha Hub)
Surgery · LINAC · Chemo · PET-CT · Tumor Board · Research · Apex Cancer Center Referral
COMPREHENSIVE TX
LQ RING 3
PILGRIMAGE TO PUBLIC HEALTH · FRAMEWORK SUMMARY
LAYER
PRIMARY CAPABILITY
KEY ACTION
Community Frontline
Jan-Bhagidari
Trust & Behaviour Observation
Building "First Conversation" and "First Decision" — ASHA/ANM digital app for symptom flagging and confident counselling
Arogya Mandirs
Universal Ring 1
Rapid Screening
5-minute GCH Screening Checklist with digital auto-referral trigger to nearest spoke or hub pathway
District Spokes
Diagnostic Ring 2
Diagnosis & Navigation
Weekly Virtual Tumor Boards connecting district clinicians to hub specialists — reducing travel burden while ensuring diagnostic accuracy
Moksha Hubs
Onco-CoE Treatment Ring 3
Comprehensive Treatment
Specialised Surgery, Radiation Therapy (LINAC + Brachytherapy), Chemotherapy, Research & Clinical Trials at GCH
11.0 · RING 0 PLATFORM CAPABILITIES — COMMUNITY EARLY DETECTION
🤝
Community Frontline Network
RING 0 · Jan-Bhagidari · Moksha Kshetras · ASHA / ANM Digital App
MODULE
ASHA/ANM Mobile Companion App — a lightweight Android-first tool for frontline health workers to log high-risk symptoms, refer citizens to Aarogya Mandirs, and track counselling outcomes.
FEATURES
Symptom checklist in Gujarati. Confident counselling protocol guide. Referral trigger → nearest Aarogya Mandir or spoke. Moksha Kshetra event scheduler for community health camps. Offline-first with ABDM sync when online.
ACTORS
ASHAsANMsPanchayat LeadersCommunity Volunteers
Platform Outcome: Converts cultural trust at Moksha Kshetras into structured referral data, feeding the Onco-CoE funnel before any clinical encounter.
📋
5-Minute GCH Screening Checklist
RING 0→1 · NAMO Screening · Digital Referral Trigger · Arogya Mandir Interface
GCH SCREENING CHECKLIST · v1.0
~5 min
ABHA ID: 14-2981-3042-7
Age: 52
Sex: Female
PIN: 360370
SECTION A · WARNING SYMPTOMS
SECTION B · RISK FACTORS
RISK SCORE
HIGH RISK — 3 flags
⚡ AUTO-REFER TO SPOKE
Nearest spoke: Jetpur District Clinic · 8.2 km · Appointment: Tomorrow 10:00 AM
Platform Outcome: Auto-referral fires the moment score threshold is crossed — zero friction, zero paper, zero missed cases.
🏥
Decentralised Spoke Diagnosis
RING 2 · District Spoke Centres (Onco-CoE Network) · Tele-oncology Navigation
MODULE
Spoke Tele-Oncology Navigation Engine — localised diagnosis and guided care navigation reducing the travel and financial burden on rural families.
FEATURES
FHIR-linked referral intake from Aarogya Mandirs. Diagnostic order set auto-generated from checklist flags. Tele-oncology video consultation with hub specialists. Day-care chemotherapy at spoke level for eligible patients. Transport coordination with patient's home pin code mapping.
IMPACT
↓ Travel burden
↑ Stage I/II detection
↑ Referral conversion
Platform Outcome: Diagnostic accuracy at the local level — no patient needs to travel 60+ km to GCH just for an initial assessment.
📡
Weekly Virtual Tumor Board
RING 2→3 · District Spoke × Hub Specialist · Early-Stage Screening Case Review
MODULE
Early Detection Virtual MDT — a weekly scheduled session distinct from the hub-level treatment tumor board. Designed for high-volume, lower-acuity screening-detected cases requiring specialist input before hub referral decision.
FEATURES
Weekly fixed slot (e.g. every Tuesday, 4:00 PM). District spoke clinicians present checklist-flagged cases. Hub oncologist reviews imaging and lab results via shared PACS/FHIR. Outcome: refer to hub, treat at spoke, or watchful waiting protocol. All decisions recorded in patient Onco-CoE pathway.
NEXT SESSION · TUE 11 MAR · 4:00 PM · 6 CASES QUEUED
GCH-ED-01 F/48 · Oral patch · Tobacco use · Gondal Spoke URGENT
GCH-ED-02 M/55 · Neck lump 3 weeks · Virpur Spoke REVIEW
GCH-ED-03 F/62 · Mammogram flag · Kagvad Mandir IMAGING
Platform Outcome: Hub specialist oversight at the spoke level — every screening-detected case gets expert review without leaving the district.

Start with 500. Scale to 500,000.

The CLI pilot enrolls 500 citizens across 5 pin codes within 25 km of Kagvad — a mix of rural, semi-urban, and tribal populations. Baseline LQ scores are established, biomarker gaps identified, and the data model validated before district-wide rollout. Expansion gates trigger at 80% pilot completion and government authority sign-off.

500
PILOT CITIZENS
5
PIN CODES
4
RINGS (0→3)
11.1 · THE THREE-RING PROGRESSIVE DIAGNOSTIC FRAMEWORK (RINGS 1–3)
Universal Ring
📍 Delivered at: Aarogya Mandir · PHC · Spoke GP

Feasible at every community touchpoint. No lab required beyond basic equipment. Covers the foundational LQ score for 100% of pilot citizens.

● MANDATORY CORE
Medical HistoryFamily HistoryPsychosocial Assessment Cognitive TestsMood AssessmentSleep Assessment Vital SignsPhysical ExamBIA (Body Composition) BP / BMI / WeightLifestyle AssessmentVaccination History Risk Scores (Q-Risk, Framingham)Urinalysis
● MANDATORY LAB
CBC (Complete Blood Count)Fasting Blood Sugar HbA1cLipid ProfileCreatinine / GFR CRP (Inflammation)TSH
LQ Weight: 40% · Establishes baseline metabolic, inflammatory, and lifestyle health profile.
Spoke Ring
📍 Delivered at: District Clinic · GCH OPD Spoke · Diagnostic Partner

Requires NABL-certified labs and ECG/imaging equipment. Targets 60% of pilot cohort based on Ring 1 risk stratification results.

● RECOMMENDED OPTIONAL
ECGVO2 Max (CPET)Carotid Ultrasound Coronary Calcium ScoreBone Mineral Density PSA (Men)Mammogram (Women)Colonoscopy (50+) Skin Cancer ScreeningOGTTInsulin + C-Peptide IGF-1 / Growth HormoneFull Hormonal Panel ESRLiver Function (ALT/AST/GGT/Bilirubin/PT/Albumin) Micronutrient PanelHeavy Metal Screen Oral Health AssessmentWearable Sleep (FDA-approved)
● CANCER-SPECIFIC SCREENING
BRCA1/2 (family risk)APOE (fam. risk) Familial Hyperlipidemia genesStool Microbiome
LQ Weight: 40% · Adds cardiovascular, hormonal, organ function, and guideline cancer screening dimensions.
Hub / CoE Ring
📍 Delivered at: GCH Hub · Apex Cancer Center · Research Protocol

Advanced diagnostics for high-risk citizens identified in Ring 1–2. Requires specialised labs and clinical oversight. Informs precision prevention strategies.

● NEEDS FURTHER VALIDATION
TMAO (cardiovascular)Galectin-3Myeloperoxidase Whole Genome / ExomeOral / Skin / Vaginal Microbiome DNA Methylation (Epigenetic Age)Immunophenotyping Glycan TestingProteomicsMetabolomics Early Cancer MarkersWhole Body MRI
⚠ RESEARCH PROTOCOL ONLY
Liquid Biopsy Telomere Length SASP Markers Non-FDA Wearables Thermography Scanning
LQ Weight: 20% · Precision longevity layer for research-track and high-risk individuals only.

The LQ is a normalised 0–100 composite score calculated from completed biomarker rings. A score of 80+ indicates optimal longevity health. 60–79 indicates moderate risk requiring lifestyle and clinical intervention. Below 60 flags high disease-risk requiring immediate clinical pathway activation.

80–100
Optimal
70–79
Good
60–69
At Risk
50–59
High Risk
<50
Critical
74 PILOT AVG · LQ SCORE 0 100
Simulated pilot cohort average
DISTRICT HEALTH INTELLIGENCE TRACKER

A dual-persona dashboard — the Hospital Administrator monitors clinical LQ trajectories and biomarker flags, while the Government Authority (CMO / Collector) tracks population-level screening compliance and district health risk distribution.

SHOWING 8 OF 500
CITIZEN / PIN CODE
LQ SCORE
RING
METABOLIC
CARDIO
CANCER RISK
Harish Patel, 58M
Kagvad · 360370
48
Ring 3
🔴 HbA1c 9.2
🟡 BP High
⚠ PSA Elevated
Meena Bhatt, 44F
Jetpur · 360370
71
Ring 2
🟢 Normal
🟢 Normal
🟡 Due Mammo
Raju Solanki, 67M
Virpur · 360380
55
Ring 2
🟡 Lipids High
🔴 CAC Score 320
🟢 Low Risk
Savita Rathod, 39F
Gondal · 360311
83
Ring 1
🟢 Optimal
🟢 Optimal
🟢 Low Risk
Dhruv Mehta, 52M
Jetpur · 360370
63
Ring 2
🟡 Pre-diabetic
🟢 Normal
🟡 Colonoscopy Due
Ananya Desai, 31F
Kagvad · 360370
88
Ring 1
🟢 Optimal
🟢 Optimal
🟢 Low Risk
Babubhai Chauhan, 71M
Virpur · 360380
44
Ring 3
🔴 Multi-flag
🔴 Angiogram Req.
🔴 PSA Critical
Lata Trivedi, 55F
Gondal · 360311
66
Ring 2
🟡 Thyroid Low
🟢 Normal
🟡 BRCA Pending
HbA1c > 7.5% 38%
BP Hypertensive 31%
Lipid Panel Abnormal 27%
Cancer Screening Overdue 44%
CRP Elevated (>3 mg/L) 22%
Cancer RiskHigh · 18%
CardiovascularMod-High · 31%
Metabolic / T2DMHigh · 38%
Neurological / CognitiveLow · 9%
Average Longevity Quotient by location
PILOT PHASE
72 360370 · Kagvad n=124 78 360311 · Gondal 65 360380 · Virpur 81 360320 · Navagadh 58 362001 · Junagadh LQ SCALE 80+ Optimal 70–79 Good 60–69 At Risk <60 High Risk
Bubble size indicates relative cohort size · Click pin code to drill down
74
AVG DISTRICT LQ
500
CITIZENS ENROLLED
23%
HIGH RISK (<60 LQ)
5
PIN CODES ACTIVE
Metabolic / Diabetes38% high risk
Cardiovascular31% moderate+
Cancer Risk (screened)18% flagged
Hormonal / Thyroid14% abnormal
Renal / Hepatic9% flagged
PILOT PHASE · 500 CITIZENS
PIN CODE / LOCATION ENROLLED RING 1 % RING 1 PROGRESS RING 2 % RING 2 PROGRESS RING 3 % AVG LQ STATUS
360370 · Kagvad / Jetpur 124 94%
61%
12% 72 IN PROGRESS
360311 · Gondal 98 100%
78%
22% 78 ON TRACK
360380 · Virpur 88 82%
39%
4% 65 LAGGING
360320 · Navagadh 112 97%
83%
28% 81 AHEAD
362001 · Junagadh (urban fringe) 78 67%
28%
2% 58 INTERVENTION REQ.
📊 Overall pilot completion: Ring 1: 88% · Ring 2: 58% · Ring 3: 14% Last synced: Today 03:45 PM · ABDM data bridge

Phase 2 expansion (5,000 citizens · 25 pin codes) unlocks when pilot Ring 1 compliance reaches ≥80% across all pin codes AND government authority CMO sign-off is received. Current status: 3 of 5 pin codes at threshold.

3/5
PIN CODES READY
60% to Phase 2
12 / HOSPITAL CAPABILITY BLUEPRINT & TECHNOLOGY REQUIREMENTS

From Clinical Capability
to Platform Intelligence

Getwell Cancer Hospital is equipped as a comprehensive tertiary oncology centre. This section maps every clinical capability to its corresponding Onco-CoE platform module, derives the technology requirements each demands, and positions all capabilities within the phased implementation roadmap.

12A · HOSPITAL CAPABILITY BLUEPRINT
🔬
Diagnostics Wing
IMAGING · ENDOSCOPY · INTERVENTIONAL
Digital X-Ray
DICOM
Fluoroscopy
DICOM
Ultrasound
DICOM
Mammography
SCREENING
CT Scanner
DICOM · AI
MRI
DICOM · AI
Endoscopy Suite
VIDEO
⚛️
Radiation & Nuclear Medicine
LINAC · BRACHY · PET-CT · SPECT
Linear Accelerator (LINAC)
DICOM-RT
CT Simulator
RT PLAN
Brachytherapy Unit
BRACHY
PET-CT
SUV · AI
Gamma Camera / SPECT
NM DOSE
Paediatric Sedation Prep Room
PEDS
🔪
Surgical Wing
OT · DSA · RECOVERY
Operating Theatres
OT MGMT
Minor OT
PROCEDURE
Pre / Post-Op
RECOVERY
DSA Suite
IR · DICOM
Endoscopy Recovery
WORKFLOW
🛏
Inpatient Wing
ICU · WARDS · SPECIALIST BEDS
SICU / HDU / ICU Beds
CRITICAL
Ward + Palliative + Paediatric
CENSUS
Clinical Trial Beds
CTMS
Immunocompromised Section
ISOLATION
Radioactive Iodine Beds
RAI · SAFETY
💉
Daycare & Chemotherapy
CHAIRS · BEDS · INFUSION
Chemotherapy Chairs
CHAIR SCHED
Chemotherapy Beds
INFUSION
Other Daycare Beds
DAYCARE
Radiology RT Recovery
RECOVERY
🚑
OPD & Emergency
CONSULTING · URGENT CARE · TRIAGE
OPD Consulting Rooms
EMR · QUEUE
ER / Urgent Care
TRIAGE AI
Teleconsultation
VIDEO
BED CAPACITY SUMMARY
ℹ️ Bed counts below are indicative placeholders — to be confirmed with hospital planning team before external distribution.
TBD
Census Beds
(Ward + ICU + Specialist)
TBD
Daycare Capacity
(Chairs + Chemo Beds)
TBD
Supportive Beds
(Palliative + Trial + Paeds)
500
Total Planned Capacity
(All Bed Types)
12B · EIGHT FUTURISTIC PLATFORM CAPABILITIES

Each of the eight capabilities below is unlocked by a specific clinical infrastructure item at GCH. The platform must be purpose-built to support these — they are not generic hospital IT features, but precision oncology workflow engines.

AI-Assisted Radiation Planning
CLINICAL TRIGGER · LINAC + CT Simulator + Brachytherapy
MODULE
Adaptive Radiotherapy Intelligence Engine — integrates with TPS (Treatment Planning System) via DICOM-RT to enable AI-assisted auto-contouring of tumour volumes and organs-at-risk.
FEATURE
AI auto-contours GTV/CTV/PTV from CT Sim data. Fraction scheduling tied to patient pathway. Brachytherapy implant workflow with dose logging. Adaptive plan modification alerts when anatomy changes mid-course.
STANDARD
DICOM-RT · FHIR ImagingStudy · HL7 RadiologyOrder · ICRU 83 dose reporting
Patient Outcome: Reduces contouring time from 2–4 hours to under 20 minutes. Adaptive planning reduces radiation toxicity by up to 30% in published trials.
☢️
Nuclear Medicine Intelligence
CLINICAL TRIGGER · PET-CT + Gamma Camera / SPECT
MODULE
Nuclear Medicine Workflow Automation — SUV (Standardised Uptake Value) trending engine with AI metabolic response assessment across treatment cycles.
FEATURE
PET-CT results auto-ingested into patient pathway. SUV baseline vs post-treatment delta calculated and flagged. SPECT dose map integration. Radioisotope inventory management with expiry and regulatory compliance tracking.
STANDARD
DICOM NM · PERCIST 1.0 · EANM radiopharmacy guidelines · HL7 NuclearMed order
Patient Outcome: AI metabolic response assessment detects treatment failure 6–8 weeks earlier than conventional imaging — enabling faster pivot to alternative regimens.
🏥
Real-Time Bed & Resource Orchestration
CLINICAL TRIGGER · All bed types — Census + Daycare + ICU + Specialist
MODULE
Unified Bed Intelligence Dashboard — single real-time view of all 500 beds across every wing: ICU, HDU, chemo chairs, clinical trial, immunocompromised, RAI isolation, palliative, paediatric, and daycare.
FEATURE
AI-driven bed demand forecasting (48-hour horizon). Auto-escalation when ICU capacity <20%. Chemo chair scheduling engine with infusion pump integration. Bed-type-specific infection control protocols triggered at admission.
STANDARD
FHIR Location · FHIR Encounter · HL7 ADT A01/A02/A03 · IHE PCD-01 pump integration
Patient Outcome: Real-time bed visibility reduces average patient placement time by 40%. Prevents inappropriate placement of immunocompromised patients in standard wards.
👶
Paediatric Oncology Pathway
CLINICAL TRIGGER · Paediatric Sedation Prep Room + Paediatric Ward Beds
MODULE
Paediatric Cancer Navigator — a dedicated care pathway engine for patients under 18, with age/weight-adjusted drug dosing, guardian consent management, and school/education coordination.
FEATURE
Weight-based chemotherapy dosing calculator (BSA/Calvert formula). Sedation pre-assessment workflow linking to prep room readiness. Paediatric-specific toxicity grading (CTCAE Paeds). Guardian-facing app with Gujarati language support. Long-term growth and development tracking post-treatment.
STANDARD
SIOPE / COG paediatric protocols · FHIR Patient (paeds) · ICD-10 paediatric oncology · CTCAE v5 Paeds
Patient Outcome: Weight-based dosing reduces chemotherapy dosing errors — a leading cause of paediatric oncology adverse events — by over 60% in digital-first centres.
🧪
Clinical Trial Management System (CTMS)
CLINICAL TRIGGER · Clinical Trial Beds + Research Platform
MODULE
Integrated CTMS — AI-powered eligibility screening against active trial protocols, automated Serious Adverse Event (SAE) reporting, and sponsor data export pipeline.
FEATURE
Active trial registry with inclusion/exclusion criteria engine. Patient EMR auto-matched to eligible trials at diagnosis. Protocol deviation alerting. eConsent with guardian workflow for paediatric trials. IND/CTRI registration tracking. GCP audit trail. Sponsor data transfer via CDISC ODM.
STANDARD
CDISC CDASH · ODM · CTRI India registry · ICH-GCP E6(R2) · FHIR ResearchStudy
Patient Outcome: AI trial matching increases clinical trial enrolment by 3–5× — giving patients access to cutting-edge therapies while generating revenue and research credibility for the hospital.
🦠
Immunocompromised Patient Protocol Engine
CLINICAL TRIGGER · Immunocompromised Section + SICU/HDU
MODULE
Infection Control & Isolation Intelligence — real-time immunosuppression scoring with automated reverse-isolation protocol triggers, visitor restriction alerts, and antibiotic stewardship integration.
FEATURE
ANC (Absolute Neutrophil Count) monitoring with auto-trigger for protective isolation when ANC <500. Antibiotic escalation protocol engine. Laminar airflow room assignment logic. Visitor management system with restriction enforcement. Fungal prophylaxis reminders. HAI (Hospital-Acquired Infection) surveillance dashboard.
STANDARD
IDSA neutropenic fever guidelines · NHSN HAI surveillance · FHIR Observation (ANC) · IPC bundle protocols
Patient Outcome: Automated neutropenic fever protocols reduce infection-related mortality in immunocompromised oncology patients by up to 25% in digital surveillance programmes.
Radioactive Iodine (RAI) Patient Management
CLINICAL TRIGGER · Radioactive Iodine Beds + Nuclear Medicine Unit
MODULE
RAI Protocol Engine — end-to-end management of I-131 therapy: dosimetry calculation, isolation countdown timer, radiation clearance verification before discharge, and AERB regulatory compliance reporting.
FEATURE
TSH suppression pre-therapy checklist. I-131 dose calculation (Marinelli formula). Real-time isolation room radiation level monitoring integration. Automatic discharge clearance workflow — radiation physicist sign-off required. Patient education module (dietary iodine restriction). Family radiation exposure advisory. AERB dose record submission.
STANDARD
AERB India radiation safety · IAEA Safety Standards · FHIR MedicationAdministration (RAI) · HL7 NuclearMed
Patient Outcome: Eliminates premature discharge of RAI patients — a significant radiation safety risk. Automated AERB reporting ensures zero regulatory non-compliance events.
🩺
DSA & Interventional Radiology Workflow
CLINICAL TRIGGER · DSA Suite + Endoscopy + Minor OT Recovery
MODULE
Interventional Radiology Orchestration — procedure scheduling, contrast allergy flagging, real-time haemodynamic monitoring integration, and procedure-specific informed consent engine.
FEATURE
IR procedure scheduler with cross-check against anticoagulation status and renal function (contrast safety). Pre-procedure checklist automation. Intra-procedure DICOM image capture to PACS. Post-procedure recovery bed assignment. TACE / TARE / embolisation procedure notes templates. Complication tracking and 30-day outcome follow-up.
STANDARD
DICOM SC · SIR procedural quality guidelines · FHIR Procedure · HL7 OrderEntry · ACR contrast guidelines
Patient Outcome: Automated contrast safety screening eliminates preventable contrast-induced nephropathy — a risk in up to 15% of oncology patients with compromised renal function.
12C · TECHNOLOGY READINESS MATRIX — CAPABILITY × PLATFORM × PHASE

Every clinical capability maps to a specific technology stack, a Onco-CoE platform module, and a deployment phase. This matrix is the basis for vendor selection, RFP specifications, and phased budget allocation.

Click a phase to filter · Click again or select All Phases to reset
12 capabilities
CAPABILITY EQUIPMENT Onco-CoE MODULE TECHNOLOGY STACK PHASE READINESS
Bed & Resource Orchestration All Bed Types · 500-Bed Unified Bed Intelligence Dashboard
FHIR LocationHL7 ADTIoT SensorsAI Forecasting
Phase 1
Design Ready
Immunocompromised Isolation Immuno Section · SICU Infection Control & Isolation Engine
FHIR ObservationANC MonitorNHSN HAIIPC Bundles
Phase 1
Design Ready
DSA / Interventional Radiology DSA Suite · Minor OT IR Orchestration Engine
DICOM SCFHIR ProcedureHL7 OrderEntryContrast Safety AI
Phase 1
Design Ready
ER Oncological Triage AI ER / Urgent Care Oncological Emergency Engine
Triage AIMASCC ScoreHL7 ADTFHIR Encounter
Phase 1
Design Ready
Chemo Chair Scheduling Chemo Chairs + Beds Smart Chemotherapy Management
Chair IoTIHE PCD-01FHIR MedAdminPump Integration
Phase 1
Core Module
AI Radiation Planning LINAC · CT Sim · Brachytherapy Adaptive Radiotherapy Intelligence Engine
DICOM-RTTPS APIAI ContouringFHIR ImagingStudy
Phase 2
Integration
Nuclear Medicine AI PET-CT · SPECT Nuclear Medicine Workflow Automation
DICOM NMPERCISTSUV EngineIsotope LIMS
Phase 2
Scoping
Paediatric Oncology Pathway Paeds Ward · Sedation Prep Paediatric Cancer Navigator
BSA DosingCTCAE PaedseConsentFHIR Patient
Phase 2
Requirements
RAI Patient Management RAI Beds · NM Unit RAI Protocol Engine
AERB ComplianceDosimetry CalcFHIR MedAdminRadiation Monitor
Phase 2
Scoping
ICU Severity Scoring SICU / HDU / ICU Critical Care Intelligence
APACHE II/IIISOFA ScoreFHIR ObservationVentilator API
Phase 2
Integration
Mammography AI Screening Mammography Unit Cancer Screening AI (CLI Ring 2)
DICOM MGCAD EngineBI-RADSFHIR DiagReport
Phase 2
Scoping
Clinical Trial Management Trial Beds · Research Centre Integrated CTMS
CDISC CDASHODMCTRI APIFHIR ResearchStudyeConsent
Phase 3
Planned
🔑 Readiness: Design Ready = architecture defined · Integration = vendor scoping active · Requirements = clinical spec in progress · Planned = Phase 3 backlog 12 capabilities · 3 phases · Est. 18-month full deployment
📡
Imaging & DICOM
DICOM-RT, NM, MG, SC · PACS/VNA · AI contouring engine · TPS API bridge · HL7 imaging orders
🔗
FHIR & HL7 Core
FHIR R4: Location, Encounter, MedAdmin, Procedure, ResearchStudy, Observation · HL7 ADT A01–A08 · ABDM PHR
⚖️
Compliance & Safety
AERB radiation safety · CDSCO drug regulations · CTRI trial registration · DISHA data sovereignty · ICH-GCP E6(R2)
🤖
AI & Decision Support
Auto-contouring · SUV trending · ANC alert engine · BI-RADS CAD · Bed forecasting · Trial eligibility matching · Contrast safety screening
13 / CLINICAL DECISION SUPPORT FRAMEWORK

From Guidelines to
Clinical Intelligence

A computable clinical decision support layer that embeds oncology guidelines from the National Cancer Grid (NCG) and National Comprehensive Cancer Network (NCCN) directly into clinical workflows — firing at the right moment, for the right patient, with the right recommendation, tagged to India's resource stratification framework and GCH's live capability registry.

13A · FRAMEWORK OVERVIEW — THE CLINICAL INTELLIGENCE PROBLEM
Protocol adherence fails when guidelines live in PDFs, not workflows.
Oncologists across India's hub-and-spoke network manage dozens of tumour types simultaneously. Without embedded decision support, guideline adherence depends entirely on individual recall — leading to variation in staging, treatment selection, and response assessment that directly affects outcomes.
Computable guidelines that fire inside the EMR at each decision point.
The Onco-CoE CDS engine converts NCG and NCCN guidelines into machine-executable rules — delivering contextual, patient-specific recommendations at diagnosis, treatment selection, radiation planning, and surveillance, with every recommendation tagged to India's E/O/O framework and GCH's capability status.
DUAL-SOURCE GUIDELINE ARCHITECTURE
🇮🇳
National Cancer Grid (NCG) — India
INDIA CONTEXTUALISATION · RESOURCE STRATIFIED · E/O/O CLASSIFICATION · AB-PMJAY LINKED
Provides the India-specific adaptation layer: Essential/Optimal/Optional classification, Ayushman Bharat reimbursability tags, equity considerations for the Gujarat catchment, and GRADE-rated evidence summaries contextualised to Indian healthcare infrastructure.
🌐
National Comprehensive Cancer Network (NCCN) — USA
INTERNATIONAL EVIDENCE BACKBONE · CATEGORY 1/2A/2B/3 · ANNUALLY UPDATED · TUMOUR-TYPE SPECIFIC
Provides the international evidence backbone: category-graded recommendations across all tumour types, continuously updated with emerging trial data, and the source framework that NCG itself adapts from. Requires institutional membership for clinical deployment.
📊
Cancer Registry · GCH Real-World Evidence
BIDIRECTIONAL LOOP · LOCAL OUTCOMES · PROTOCOL DEVIATION AUDIT · LEARNING HEALTH SYSTEM
The registry feeds the CDS (which tumour types to prioritise) and the CDS feeds the registry (real-world outcomes for each protocol). Over time, GCH generates its own local evidence layer — deviation rates, outcomes by stage, population-specific response patterns.
GUIDELINE TO PATIENT CARE — TRANSLATION PIPELINE
NCCN / International Evidence
INTERNATIONAL · CATEGORY GRADED
Published oncology evidence. Category 1 = uniform high-level consensus. Source for NCG adaptation process.
NCG Contextualisation
INDIA · E/O/O · GRADE · AB-PMJAY
PICO-structured review. GRADE evidence rating. E/O/O classification. Cost-effectiveness analysis. AB-PMJAY HBP linkage.
Computable CDS Rules
FHIR · CQL · CDS HOOKS
Guidelines encoded as FHIR PlanDefinitions and CQL logic libraries. CDS Hooks fire on clinical triggers (order entry, diagnosis code, staging).
Patient Context Binding
REAL-TIME · FHIR PATIENT RECORD
CDS matched to patient: diagnosis, stage, prior treatment, ECOG status, comorbidities, genetic markers, ABHA record, AB-PMJAY eligibility.
Clinician Workflow Card
AT POINT OF CARE · EMR EMBEDDED
Recommendation card shown in EMR. NCG E/O/O tag, GRADE rating, AB-PMJAY flag, GCH capability status, deviation capture if overridden.
ESSENTIAL
Evidence-based + widely available + cost-justified. If GCH cannot deliver → mandatory referral to Apex Cancer Center (Tier 0). Linked to AB-PMJAY Health Benefit Packages.
OPTIMAL
Evidence-based + cost-effective, requires specialist infrastructure. GCH qualifies for most Optimal recommendations. Requires equipment/expertise confirmation via Capability Registry.
OPTIONAL
State-of-the-art, purely evidence-driven, no cost ceiling. Typically Phase 3 capabilities. Clinical trials, advanced molecular profiling, immunotherapy combinations.
HIGH
True effect close to estimated. RCT-level evidence. Clinician can act with high confidence.
MODERATE
Probably close to true effect. CDS card shown with contextual caveat for clinical judgment.
LOW / VERY LOW
True effect may differ markedly. Card surfaced as advisory only. Deviation capture mandatory.
NCCN Categories: Cat 1 = uniform high-consensus · Cat 2A = lower-level evidence, uniform consensus · Cat 2B = lower-level, non-uniform consensus · Cat 3 = major disagreement

The Capability Registry is a live, structured record of every clinical capability at GCH — updated as equipment is commissioned, staff are trained, and accreditations are received. The CDS engine queries the registry before surfacing any recommendation: if GCH cannot deliver an Essential recommendation, the system automatically generates an Apex Cancer Center referral pathway. As GCH capabilities grow, the referral threshold dynamically recalibrates — without any manual update to the CDS rules.

Full Capability
DELIVER RECOMMENDATION
~
Partial Capability
DELIVER WITH CAVEAT
Refer to Tier 0
AUTO-GENERATE APEX REFERRAL
LINAC · Brachytherapy · CT Sim
RADIATION ONCOLOGY
PET-CT · SPECT · MRI · CT
IMAGING & NUCLEAR MED
~
Whole Genome Sequencing
MOLECULAR PROFILING
Surgery · DSA · OT Complex
SURGICAL ONCOLOGY
~
Proton Beam Therapy
ADVANCED RADIATION
CAR-T Cell Therapy
CELLULAR THERAPY
13B · FIVE TUMOUR PROTOCOL ENGINES — REGIONAL PRIORITY CANCERS

Five tumour types selected based on Gujarat/Saurashtra epidemiology, GCH equipment coverage, and NCG/NCCN guideline availability. Additional tumour types will be incorporated as the cancer registry matures and incidence patterns are confirmed. Head & Neck is presented as the full worked example given its regional prevalence and multi-modal treatment complexity.

🎗
Head & Neck Cancer
#1 REGIONAL BURDEN · TOBACCO/ARECA FULL WORKED EXAMPLE
Oral cavity, oropharynx, larynx, hypopharynx, nasopharynx, thyroid, salivary glands. Most complex multi-modal pathway: surgery + radiation + chemo + brachytherapy + reconstruction + speech rehabilitation. Oral cancer is the leading cancer in males across Gujarat due to tobacco and areca nut exposure.
GUIDELINE SOURCES
NCG Head & Neck NCCN HNCC
1
Diagnosis & Staging
CDS Hook: patient-view ESSENTIAL GRADE HIGH NCCN Cat 1
CDS fires on ICD-10 code entry (C00–C14 oral/oropharynx, C32 larynx, C73 thyroid). Surfaces mandatory staging workup: clinical examination + endoscopy + CT neck/chest with contrast + MRI for skull base/perineural involvement + PET-CT for Stage III/IV. HPV/p16 testing triggered for oropharyngeal SCC.
ICD-10 C00–C14 FHIR Condition CT neck/chest PET-CT Stage III/IV HPV/p16 OPx SCC FNAC biopsy
✓ GCH Full Capability — CT, MRI, PET-CT, Endoscopy, Pathology all on-site
2
Multidisciplinary Tumour Board Review
CDS Hook: order-sign ESSENTIAL GRADE HIGH NCCN Cat 1
CDS alert fires if treatment plan is ordered without a documented MDT review for T2+ disease. Blocks single-specialty treatment initiation. Surfaces MDT scheduling module. Minimum quorum: surgical oncologist + radiation oncologist + medical oncologist + pathologist + radiologist. MDT decision recorded in FHIR CarePlan.
FHIR CarePlan MDT quorum check order-sign hook T2+ gate
✓ GCH Virtual Tumor Board infrastructure — weekly MDT schedule operational
3
Treatment Selection — Surgery vs CRT vs Organ Preservation
CDS Hook: order-select OPTIMAL GRADE HIGH NCCN Cat 1/2A
CDS presents treatment pathway options based on: tumour site, T/N stage, HPV status (oropharynx), ECOG performance status, patient age, organ preservation intent. Key decision nodes: early stage (T1/T2 N0) → surgery or definitive RT. Advanced (T3/T4 or N+) → concurrent chemoradiation (cisplatin preferred, NCG Essential). Larynx: organ preservation protocol (RTOG 91-11 schema) vs total laryngectomy.
T/N staging ECOG status HPV flag Cisplatin CRT FHIR ServiceRequest AB-PMJAY eligible
✓ GCH Full Capability — Surgery + LINAC + Concurrent Chemo all on-site
4
Radiation Planning — IMRT / VMAT / Brachytherapy
CDS Hook: order-sign (RT) OPTIMAL GRADE MOD NCCN Cat 2A
CDS fires on RT order entry. Surfaces IMRT/VMAT preference for head and neck (parotid sparing, cord constraint). Dose prescription check: 70 Gy/35 fractions gross tumour, 60 Gy elective neck. Brachytherapy pathway for lip/oral cavity recurrence. AI auto-contouring integration from Section 12 Adaptive RT module. OAR dose constraint alerts (spinal cord ≤45 Gy, parotid mean ≤26 Gy).
IMRT/VMAT 70 Gy/35# check OAR constraints DICOM-RT Parotid sparing Brachy lip/oral
✓ GCH Full Capability — LINAC, CT Sim, Brachytherapy, AI contouring pipeline
5
Response Assessment
CDS Hook: patient-view (12wk) ESSENTIAL GRADE HIGH NCCN Cat 1
CDS alert fires 12 weeks post-completion of CRT. Mandates response assessment: clinical exam + CT neck/chest + PET-CT (if PET-staged). Neck dissection decision: PET-CT CR at 12 weeks → observation (NCCN Cat 1, PET-NECK trial). PET-CT incomplete response → salvage neck dissection. Nuclear medicine AI module (Section 12) calculates SUV delta from baseline PET. Residual disease → salvage surgery discussion triggered in MDT.
12-week gate PET-CT CR check SUV delta AI RECIST 1.1 FHIR Observation Salvage trigger
✓ GCH Full Capability — PET-CT + Nuclear Medicine AI pipeline on-site
6
Surveillance & Survivorship
CDS Hook: patient-view (scheduled) ESSENTIAL GRADE MOD NCCN Cat 2A
Surveillance schedule auto-generated in Onco-CoE pathway. Year 1: clinic every 1–3 months. Year 2: every 2–6 months. Year 3–5: every 4–8 months. 5+ years: annually. Thyroid function monitoring (post-neck irradiation, annual TSH). Dental review pre/post RT (osteoradionecrosis prevention). Speech/swallow rehabilitation pathway. Tobacco/areca cessation counselling re-triggered at each visit if use documented at baseline.
Surveillance calendar TSH annual Dental review Speech rehab Tobacco cessation FHIR CareTeam
~ Partial — Survivorship clinic and speech rehab pathway under development (Phase 2)
FOUR ADDITIONAL TUMOUR PROTOCOL FRAMEWORKS
🎀
Breast Cancer
#1 FEMALE · GUJARAT
Screening-detected via CLI Ring 2 mammography · Surgery + Chemo + LINAC + Hormone + Targeted (Herceptin)
NCG Breast NCCN BC
KEY CDS DECISION NODES
01
BI-RADS score → biopsy triggerE
02
HER2/ER/PR/Ki67 → subtype classification + treatment armE
03
BCS vs mastectomy decision (tumour:breast ratio, multifocality)O
04
Neoadjuvant chemo protocol (AC-T, ddAC-T, TCH for HER2+)E
05
BRCA1/2 mutation → enhanced surveillance + surgical counsellingOp
06
Post-surgery adjuvant RT target volume (whole breast vs partial)O
GCH CAPABILITY READINESS
85% · BRCA genomics at spoke or Apex Cancer Center referral
🔬
Cervical Cancer
HIGH RURAL BURDEN · HPV GAP
High prevalence in rural Saurashtra · Surgery (early) + CRT (locally advanced) + Brachytherapy integral
NCG Cervix NCCN Cx Ca
KEY CDS DECISION NODES
01
FIGO staging (2018) → treatment arm selectionE
02
Stage IA1/IA2 → fertility-sparing option counsellingO
03
IB2–IVA → concurrent cisplatin CRT + brachytherapy (EBRT+BT)E
04
Brachytherapy technique (ICBT vs ISBT) based on tumour geometryO
05
MRI-guided adaptive brachytherapy (GEC-ESTRO)Op
06
Post-treatment surveillance + VIA/HPV co-test at spokesE
GCH CAPABILITY READINESS
90% · MRI-guided brachy Phase 2 upgrade
🫁
Gastrointestinal (CRC + Gastric)
RISING INCIDENCE
Colorectal + Gastric + Hepatobiliary · Surgery + Chemo + TACE/TARE via DSA · Endoscopy-linked workflow
NCG GI NCCN CRC/Gastric
KEY CDS DECISION NODES
01
Colonoscopy findings → NICE/NCG polyp management pathwayE
02
MSI/MMR status → immunotherapy eligibility (pembrolizumab)Op
03
RAS/BRAF mutation → targeted therapy selection (FOLFOX/FOLFIRI + bevacizumab/cetuximab)O
04
Liver metastasis resectability assessment → TACE/surgery/ablation pathwayO
05
Rectal cancer: MRI staging → neoadjuvant CRT vs upfront surgeryE
06
HER2 testing gastric/GEJ → trastuzumab eligibilityO
GCH CAPABILITY READINESS
75% · MSI/MMR molecular testing + TARE require Phase 2 build
🫁
Lung Cancer (NSCLC + SCLC)
TOBACCO BURDEN · PET-CT CRITICAL
NSCLC (adenocarcinoma, SCC) + SCLC · PET-CT staging essential · EGFR/ALK/ROS1 molecular reflex testing
NCG Lung NCCN NSCLC/SCLC
KEY CDS DECISION NODES
01
PET-CT mandatory for staging before treatment (Stage I–III NSCLC)E
02
EGFR/ALK/ROS1/KRAS/PD-L1 reflex panel → targeted or IO therapy armO
03
Stage IIIA resectability MDT decision → surgery vs concurrent CRTE
04
SBRT for early-stage medically inoperable NSCLC (SABR protocol)O
05
SCLC: LD-SCLC → concurrent chemo-RT + PCI. ED-SCLC → chemo + atezolizumabE
06
Immunotherapy eligibility: PD-L1 TPS ≥50% + no driver mutation → pembrolizumab 1LOp
GCH CAPABILITY READINESS
70% · Molecular panel (EGFR/ALK) + SBRT capability Phase 2; IO therapy Phase 3
📊
Cancer Registry Expansion Gate: Additional tumour types (thyroid, bladder, haematological malignancies, bone/soft tissue sarcoma, CNS) will be incorporated into the CDS framework as the GCH cancer registry matures and local incidence patterns are confirmed. Registry data → protocol prioritisation → CDS build → outcomes back to registry.
13C · TECHNOLOGY INTEGRATION ARCHITECTURE

Clinical Decision Support is not a single product — it is a capability stack that must be assembled across five distinct layers, each with its own complexity, data requirements, and build timeline. The full CDS framework for five tumour types is an 18–24 month implementation. However, the architecture is designed to deliver clinical value from Month 1 onwards through a phased build: foundational EMR integration and the first Head & Neck protocol engine in Phase 1, expanding to all five tumour types with molecular decision support by Phase 3.

PHASE 1 · M1–6
Foundation & H&N Engine
CDS Hooks integration, FHIR Patient/Condition/ServiceRequest, Head & Neck 6-node protocol engine, Capability Registry v1, NCG E/O/O tag system, AB-PMJAY eligibility flags.
PHASE 2 · M7–12
Breast + Cervical Engines
Breast and Cervical protocol engines. BI-RADS AI integration. Brachytherapy workflow CDS. Molecular subtype routing (HER2/ER/PR). FIGO staging CQL logic. MDT deviation audit system.
PHASE 3 · M13–24
GI + Lung + Molecular CDS
GI and Lung engines. RAS/BRAF/EGFR/ALK routing. PD-L1/immunotherapy eligibility. MSI/MMR CDS. Cancer registry feedback loop. NCCN live update pipeline. Learning health system activation.
⚠️ NCCN Licensing Note: Clinical deployment of NCCN guideline content requires institutional membership. GCH should initiate NCCN member institution application as part of Phase 1 procurement. NCG guidelines are freely available under CC BY-NC-ND. Budget line required for NCCN annual membership and content licensing.
Layer 1 — Guideline Ingestion
FHIR PLANDEFINITION · CQL LIBRARIES · NCG PDF PARSING
NCG and NCCN guidelines converted from document form into machine-executable logic. Each recommendation encoded as a FHIR PlanDefinition resource with CQL (Clinical Quality Language) conditions. Ingestion pipeline: PDF → structured extraction → PICO mapping → CQL authoring → PlanDefinition publish to FHIR server. Triggers: ICD-10 diagnosis codes, SNOMED CT procedure codes, LOINC observation codes.
FHIR PlanDefinition CQL R1.5 SNOMED CT ICD-10 LOINC
Layer 2 — CDS Hooks Runtime
REST API · HOOK TYPES · EMR INTEGRATION POINT
CDS Hooks (HL7 standard) provides the REST API that fires CDS logic inside the EMR at predefined clinical moments. Hook types used: patient-view (opens patient chart), order-select (clinician selects a drug/procedure), order-sign (signs an order), appointment-book. Each hook sends a FHIR context bundle to the CDS server and receives recommendation "cards" back — rendered inline in the clinical workflow without leaving the EMR.
CDS Hooks 2.0 patient-view order-select order-sign SMART on FHIR
Layer 3 — Patient Context Binding
FHIR R4 PATIENT RECORD · REAL-TIME MATCHING · ABHA INTEGRATION
The CDS engine queries the patient's FHIR record at hook-fire time to personalise recommendations. Resources consumed: Patient (demographics, ABHA ID, AB-PMJAY eligibility), Condition (diagnosis + ICD-10), Observation (lab values, ECOG status, biomarker results), MedicationStatement (prior treatment), Procedure (prior surgeries, RT), AllergyIntolerance (contraindications). Genetic markers (EGFR/ALK/HER2/BRCA) stored as FHIR MolecularSequence or DiagnosticReport.
FHIR R4 ABHA ID FHIR Condition FHIR Observation MolecularSequence ABDM PHR
Layer 4 — NCG E/O/O + Capability Registry Filter
DYNAMIC REFERRAL LOGIC · LIVE CAPABILITY REGISTER · AB-PMJAY TAGS
Before surfacing any recommendation, the CDS engine queries the GCH Capability Registry to check delivery status. Essential recommendation + GCH registry = "refer" → auto-generates Apex Cancer Center referral FHIR ServiceRequest. Optional recommendations tagged with capability phase (Phase 1/2/3). AB-PMJAY eligibility flag injected from patient's ABHA record. Every recommendation card displays: NCG tier, NCCN category, GRADE level, capability status, and AB-PMJAY reimbursability in a single structured banner.
Capability Registry API FHIR ServiceRequest E/O/O tags AB-PMJAY flag Apex Cancer Center referral path
Layer 5 — Audit, Deviation & Learning Loop
DEVIATION CAPTURE · CANCER REGISTRY FEED · OUTCOMES EVIDENCE
When a clinician overrides a CDS recommendation, the deviation is captured with a mandatory reason code (patient preference, contraindication, clinical judgment, resource unavailability). Deviation rates by protocol, tumour type, and clinician are tracked on the Quality Dashboard. All treatment decisions feed the cancer registry as real-world outcomes. Over time, this creates a local evidence layer: GCH-specific response rates, toxicity patterns, and survival outcomes by protocol — enabling guideline feedback to NCG and informing future adaptations.
FHIR AuditEvent Deviation codes Cancer Registry API Quality Dashboard NCG feedback loop
LICENSING & MEMBERSHIP
NCCN institutional membership application
NCG guidelines (CC BY-NC-ND, free to use)
SNOMED CT India NRC licence
LOINC (free open licence)
CDS Hooks SMART app registration
TECHNICAL INFRASTRUCTURE
FHIR R4 server (HAPI FHIR or Azure Health)
CQL execution engine (CQF Ruler)
EMR CDS Hooks endpoint configuration
Capability Registry microservice
ABDM ABHA identity integration
CLINICAL & REGULATORY
NCG GDG clinical validation of encoded protocols
CDSCO SaMD classification assessment
DISHA compliance review for CDS data flows
Clinical informaticist hire / partnership
AB-PMJAY HBP linkage verification per protocol